University Malaya Medical Centre

Kuala Lumpur, Malaysia

23 recruiting

Showing 120 of 21 trials

Recruiting
Phase 1Phase 2

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled55 locationsNCT06385080
Recruiting
Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC300 enrolled93 locationsNCT06120140
Recruiting
Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled53 locationsNCT07225946
Recruiting
Phase 2Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease
Janssen Research & Development, LLC1,092 enrolled324 locationsNCT07196722
Recruiting
Phase 3

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Heart FailureSystemic Inflammation
Novo Nordisk A/S680 enrolled239 locationsNCT06200207
Recruiting
Phase 3

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation

Heart Failure
Novo Nordisk A/S5,600 enrolled1117 locationsNCT05636176
Recruiting
Phase 2

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Chronic Kidney Disease
Novo Nordisk A/S465 enrolled147 locationsNCT06717698
Recruiting
Phase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled565 locationsNCT07241390
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Extensive-stage Small-cell Lung Cancer
Bristol-Myers Squibb530 enrolled184 locationsNCT06646276
Recruiting
Phase 3

A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)

Non-small Cell Lung Cancer (NSCLC)
Amgen750 enrolled379 locationsNCT05920356
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled301 locationsNCT07196748
Recruiting
Phase 1

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Metastatic Breast CancerHER2-negative Breast CancerAdvanced Solid Tumor+6 more
BeiGene300 enrolled63 locationsNCT06120283
Recruiting
Phase 3

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Gilead Sciences695 enrolled204 locationsNCT06801834
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled231 locationsNCT06662786
Recruiting
Phase 2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled229 locationsNCT06750094
Recruiting
Phase 3

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals216 enrolled99 locationsNCT06230224
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting

Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC

Non-small Cell Lung CancerALK-Positive Lung Cancer
National Cancer Centre, Singapore50 enrolled5 locationsNCT04087473
Recruiting
Phase 2

A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)

Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
University of Malaya63 enrolled1 locationNCT05286619